Relative dose intensity (RDI) is calculated by comparing what?

Relative dose intensity (RDI) is an important measure in oncology that allows healthcare professionals to assess how much of the planned chemotherapy dose a patient actually received during their treatment. It is specifically calculated by comparing the actual dose administered to the planned or intended dose.

This calculation is crucial because it helps determine the effectiveness and tolerability of the chemotherapy regimen. A lower RDI can indicate that a patient may not have received enough of the drug due to dose reductions or delays, which can impact treatment outcomes. Monitoring RDI can guide clinicians in making necessary adjustments to therapy to ensure it remains effective while managing side effects.

The other options do not relate to RDI. Calculations involving patient weight and height are more relevant to dosing but not to RDI. Symptom relief versus drug side effects pertains to patient quality of life and treatment tolerability but does not provide a numerical measure of dose delivery. Initial response to treatment focuses on how well the cancer responds to intervention rather than how much treatment was delivered compared to what was planned.